Several brokerages have updated their recommendations and price targets on shares of Cempra (NASDAQ: MLNT) in the last few weeks:

  • 12/1/2017 – Cempra was downgraded by analysts at ValuEngine from a “sell” rating to a “strong sell” rating.
  • 11/30/2017 – Cempra was upgraded by analysts at Gabelli from a “sell” rating to a “hold” rating.
  • 11/30/2017 – Cempra was upgraded by analysts at Ladenburg Thalmann Financial Services from a “neutral” rating to a “buy” rating.
  • 11/16/2017 – Cempra was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Cempra Holdings, LLC is a pharmaceutical company engaged in developing antibiotics for the treatment of bacterial infectious diseases. It focuses on developing antibiotics for treating respiratory tract, skin and skin structure infections and to target the growing problem of antimicrobial resistance. Cempra Holdings, LLC is headquartered in Chapel Hill, North Carolina. “
  • 11/10/2017 – Cempra was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Cempra Holdings, LLC is a pharmaceutical company engaged in developing antibiotics for the treatment of bacterial infectious diseases. It focuses on developing antibiotics for treating respiratory tract, skin and skin structure infections and to target the growing problem of antimicrobial resistance. Cempra Holdings, LLC is headquartered in Chapel Hill, North Carolina. “
  • 11/8/2017 – Cempra was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 11/1/2017 – Cempra was upgraded by analysts at Robert W. Baird from an “underperform” rating to a “neutral” rating. They now have a $2.00 price target on the stock.
  • 10/26/2017 – Cempra had its “neutral” rating reaffirmed by analysts at Jefferies Group LLC.
  • 10/17/2017 – Cempra was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Cempra Holdings, LLC is a pharmaceutical company engaged in developing antibiotics for the treatment of bacterial infectious diseases. It focuses on developing antibiotics for treating respiratory tract, skin and skin structure infections and to target the growing problem of antimicrobial resistance. Cempra Holdings, LLC is headquartered in Chapel Hill, North Carolina. “
  • 10/10/2017 – Cempra was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Cempra Holdings, LLC is a pharmaceutical company engaged in developing antibiotics for the treatment of bacterial infectious diseases. It focuses on developing antibiotics for treating respiratory tract, skin and skin structure infections and to target the growing problem of antimicrobial resistance. Cempra Holdings, LLC is headquartered in Chapel Hill, North Carolina. “

Shares of Cempra, Inc. (MLNT) traded down $0.35 on Thursday, hitting $15.60. 87,900 shares of the stock traded hands, compared to its average volume of 226,336. Cempra, Inc. has a twelve month low of $10.25 and a twelve month high of $40.00. The company has a debt-to-equity ratio of 0.03, a current ratio of 11.49 and a quick ratio of 11.49.

Melinta Therapeutics, Inc, formerly Cempra, Inc, is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP).

Receive News & Ratings for Cempra Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cempra Inc and related companies with MarketBeat.com's FREE daily email newsletter.